G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
October 16 2023 - 9:00AM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, today announced that multiple abstracts have been accepted
for poster presentation at the upcoming 2023 American Society of
Clinical Oncology (ASCO) Quality Care Symposium, held October 27th
and 28th in Boston, MA. A copy of the posters will be made
available on the G1 Therapeutics website following the
presentations here.
“The important research being presented at this year’s ASCO
Quality Care Symposium highlights the significant burden of
chemotherapy-induced myelosuppression and the real-world clinical
impact of treatment with trilaciclib in patients with
extensive-stage small cell lung cancer," said Raj Malik, M.D.,
Chief Medical Officer of G1 Therapeutics. “Real-world evidence is
essential to deepening our collective understanding of the impact
of treatment on patient outcomes."
Burden of Myelosuppression in Extensive-Stage Small-Cell Lung
Cancer Patients Receiving Chemotherapy: Retrospective Analysis of
Real-World Data from Tennessee Oncology. Blakely, L.J. et al.
Abstract 364. Poster Session A, Poster Board F21. Friday October
27: 11:30 AM - 1:00 PM ET; 5:30 - 6:30 PM ET
Myelosuppression and Healthcare Utilization Among Patients with
Chemotherapy-Treated Extensive-Stage Small Cell Lung Cancer
(ES-SCLC) with and without Trilaciclib from Community Oncology
Practices. Gajra, A. et al. Abstract 527. Poster Session B, Poster
Board L2. Saturday, October 28: 7:00 AM - 8:00 AM; 11:45 AM - 1:00
PM ET
Assessment Of Hospitalizations and Cytopenia Events Among
Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Receiving Chemotherapy with Trilaciclib. Huang, H. et al. Abstract
531. Poster Session B, Poster Board L6. Saturday, October 28: 7:00
AM - 8:00 AM; 11:45 AM - 1:00 PM ET
Patient Characteristics Associated with Myelosuppression Among
Patients with Extensive-Stage Small Cell Lung Cancer Treated with
Chemotherapy in The Community Oncology Setting. Goldschmidt, J. et
al. Abstract 289. Poster Session B, Poster Board J24. Saturday,
October 28: 7:00 AM - 8:00 AM; 11:45 AM - 1:00 PM ET
About G1 TherapeuticsG1 Therapeutics, Inc. is a
commercial-stage biopharmaceutical company focused on the
development and commercialization of next generation therapies that
improve the lives of those affected by cancer, including the
Company’s first commercial product, COSELA® (trilaciclib). G1 has a
deep clinical pipeline and is executing a development plan
evaluating trilaciclib in a variety of solid tumors, including
breast, lung, and bladder cancers. G1 Therapeutics is based in
Research Triangle Park, N.C. For additional information, please
visit www.g1therapeutics.com and follow us on X (formerly known as
Twitter) @G1Therapeutics and LinkedIn
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and
the COSELA logo are trademarks of G1 Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend" and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this press release include, but are
not limited to our ability to deepen the understanding of the
effects of treatment with trilaciclib on patient outcomes. Each of
these forward-looking statements involves risks and uncertainties.
Factors that may cause the company’s actual results to differ from
those expressed or implied in the forward-looking statements in
this press release are discussed in the company’s filings with
the U.S. Securities and Exchange Commission, including the
"Risk Factors" sections contained therein and include, but are not
limited to, the company’s dependence on the commercial success of
COSELA (trilaciclib); the development and commercialization of new
drug products is highly competitive; the company’s ability to
complete clinical trials for, obtain approvals for and
commercialize any of its product candidates; the company’s initial
success in ongoing clinical trials may not be indicative of results
obtained when these trials are completed or in later stage trials;
the inherent uncertainties associated with developing new products
or technologies and operating as a commercial-stage company; and
market conditions. Except as required by law, the company assumes
no obligation to update any forward-looking statements contained
herein to reflect any change in expectations, even as new
information becomes available.
G1 Therapeutics Contacts:
Will RobertsVice President, Investor Relations & Corporate
Communications919-907-1944 wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Apr 2024 to May 2024
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From May 2023 to May 2024